- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07950150
Pomegranate-Prebiotic Supplementation for Sarcopenic Obesity
The Efficacy of Pomegranate-Prebiotic Supplementation to Enhance Beneficial Phytochemicals in Older Adults With Sarcopenic Obesity
Sarcopenic obesity (SO) in older adults involves the co-occurrence of skeletal muscle decline and excessive body fat. This project investigates the gut-muscle axis, specifically how gut bacteria convert dietary polyphenols (such as ellagic acid found in pomegranates) into a muscle-protecting metabolite called Urolithin A (UA). This study is a randomized crossover pilot trial in 30 older adults with SO. It tests whether combining a pomegranate extract supplement with a prebiotic (Fructo-oligosaccharides, or FOS) increases the body's production of UA more effectively than pomegranate extract alone over a 7-day period.
연구 개요
상태
상세 설명
Background and Rationale Sarcopenic obesity (SO) is a major public health challenge that significantly increases the risk of frailty, functional dependence, and metabolic comorbidities in aging populations. Current lifestyle and nutritional interventions often fail to address the underlying mitochondrial dysfunction and chronic low-grade inflammation central to the pathogenesis of SO. Recently, the gut-muscle axis has emerged as a therapeutic target. Urolithin A (UA) is a gut-derived microbial metabolite synthesized from dietary ellagitannins and ellagic acid (abundant in pomegranates) that activates mitophagy and improves mitochondrial health in skeletal muscle. However, UA synthesis is highly variable and depends on individual gut microbial composition, which is often compromised in older adults with obesity and sarcopenia (dysbiosis). Recent evidence suggests that prebiotics like Fructo-oligosaccharides (FOS) can promote the specific bacterial strains (Bifidobacterium and Enterococcus species) required for the two-step bioconversion of ellagic acid into UA.
This is a clinical pilot trial designed to test the feasibility and biological efficacy of a synergistic nutritional intervention. A total of 30 older adults diagnosed with SO will be enrolled in a randomized crossover trial. Each participant will undergo two 7-day intervention periods separated by a 14-day washout period.
Intervention A includes pomegranate extract alone (yielding 200 mg/day of ellagic acid). Intervention B includes pomegranate extract (yielding 200 mg/day of ellagic acid) combined with FOS prebiotic powder (5 g/day).
Because each participant serves as their own control, the crossover design eliminates the confounding effect of individual variability in baseline gut microbiome composition. The primary outcome is the within-participant difference in 24-hour urinary UA excretion (normalized to creatinine) between the combined intervention and the single-component intervention. Secondary outcomes include changes in fecal urolithin concentrations and shifts in gut microbiota composition assessed via 16S rRNA sequencing. Findings will inform the design of a fully powered randomized controlled trial testing this cost-effective synbiotic strategy for managing SO.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Ka Hei Kenneth Lo, PhD
- 전화번호: 852-3400-8778
- 이메일: kenneth.kh.lo@polyu.edu.hk
연구 장소
-
-
-
Hong Kong, 중국
- The Hong Kong Polytechnic University
-
연락하다:
- Ka Hei Kenneth Lo, PhD
- 전화번호: 852-3400-8778
- 이메일: kenneth.kh.lo@polyu.edu.hk
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 65 years or older.
- Confirmed diagnosis of Sarcopenic Obesity (SO) according to 2022 ESPEN-EASO consensus and AWGS criteria:
- Obesity Component: BF% ≥25% (men) / ≥35% (women); OR BMI ≥23kg/m2; OR waist circumference >90cm (men) / >80cm (women).
- Sarcopenia Component: Low relative skeletal muscle mass combined with low handgrip strength (<28 kg men / <18kg women) and/or low physical performance (5-time chair stand ≥12s or gait speed <1.0m/s).
- Able and willing to provide informed consent.
- Willing and able to comply with all study procedures, dietary supplementation, and sample collections (24-hour urine and fecal samples).
Exclusion Criteria:
- Current regular intake of pomegranate, ellagitannin, or prebiotic supplements.
- Known hypersensitivity or allergy to pomegranate or fructo-oligosaccharides (FOS).
- History of renal diseases, renal replacement therapy, active cancer, severe cognitive impairment, or severe cardiac or hepatic dysfunction.
- Exposure to systemic antibiotics within 3 months prior to enrollment.
- Current participation in any other active interventional clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Pomegranate Extract Alone (Active Control)
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract alone. |
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days. |
|
실험적: Pomegranate Extract + Fructo-oligosaccharides (FOS)
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract in combination with FOS prebiotic powder. |
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days. Two teaspoons (5 g/day) daily of Source Naturals FOS Powder. Provided as pre-measured daily sachets of bulk powder to be mixed with water, juice, or food and consumed orally for 7 consecutive days. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
24-Hour Urinary Urolithin A Excretion
기간: Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).
|
Within-participant difference in 24-hour total urinary urolithin A excretion normalized to urinary creatinine between the Pomegranate Extract + FOS intervention period and the Pomegranate Extract Alone intervention period. Measured via UHPLC-MS/MS. |
Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
24-Hour Total Urinary Urolithins Profile
기간: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Total excretion of urolithin metabolites and intermediates (including urolithin B and urolithin C) measured in 24-hour batch urine samples using UHPLC-MS/MS. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
|
Gut Microbiota Composition
기간: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Relative abundance and community structure of target gut bacteria (including Bifidobacterium species and urolithin-converting taxa) determined by 16S rRNA gene sequencing (V3-V4 hypervariable region) on an Illumina MiSeq platform. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
|
Fecal Urolithin Concentrations
기간: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Concentrations of urolithin A, urolithin B, and urolithin C in self-collected homogenized fecal samples, extracted and quantified via UHPLC-MS/MS. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HSEARS20260821008
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .